{"id":"https://openalex.org/W4396561073","doi":"https://doi.org/10.1158/1535-7163.mct-23-0784","title":"MYTX-011: A pH-Dependent Anti\u2013c-MET Antibody\u2013Drug Conjugate Designed for Enhanced Payload Delivery to c-MET\u2013Expressing Tumor Cells","display_name":"MYTX-011: A pH-Dependent Anti\u2013c-MET Antibody\u2013Drug Conjugate Designed for Enhanced Payload Delivery to c-MET\u2013Expressing Tumor Cells","publication_year":2024,"publication_date":"2024-04-26","ids":{"openalex":"https://openalex.org/W4396561073","doi":"https://doi.org/10.1158/1535-7163.mct-23-0784","pmid":"https://pubmed.ncbi.nlm.nih.gov/38684230","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11372359"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-23-0784","doi":"https://doi.org/10.1158/1535-7163.mct-23-0784","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-23-0784","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1158/1535-7163.mct-23-0784","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002466763","display_name":"Nimish Gera","orcid":"https://orcid.org/0000-0003-2453-9468","observed_orcids":["https://orcid.org/0000-0003-2453-9468"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nimish Gera","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0003-2453-9468","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049549711","display_name":"Kyle M. Fitzgerald","orcid":"https://orcid.org/0009-0000-0603-770X","observed_orcids":["https://orcid.org/0009-0000-0603-770X"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kyle M. Fitzgerald","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0000-0603-770X","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075560322","display_name":"Vijay Ramesh","orcid":"https://orcid.org/0009-0009-8190-2965","observed_orcids":["https://orcid.org/0009-0009-8190-2965"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vijay Ramesh","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0009-8190-2965","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103230948","display_name":"Purvi Patel","orcid":"https://orcid.org/0009-0000-3804-2028","observed_orcids":["https://orcid.org/0009-0000-3804-2028"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Purvi Patel","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0000-3804-2028","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010241998","display_name":"Deepak Kanojia","orcid":"https://orcid.org/0000-0003-4295-4972","observed_orcids":["https://orcid.org/0000-0003-4295-4972"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deepak Kanojia","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0003-4295-4972","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074767968","display_name":"Federico Colombo","orcid":"https://orcid.org/0000-0002-3893-025X","observed_orcids":["https://orcid.org/0000-0002-3893-025X"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Federico Colombo","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0002-3893-025X","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036690734","display_name":"Lena Kien","orcid":"https://orcid.org/0009-0003-5530-2209","observed_orcids":["https://orcid.org/0009-0003-5530-2209"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lena Kien","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0003-5530-2209","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068701308","display_name":"Simon Aoyama","orcid":"https://orcid.org/0009-0003-9129-5739","observed_orcids":["https://orcid.org/0009-0003-9129-5739"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simon Aoyama","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0003-9129-5739","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101845409","display_name":"Lihui Xu","orcid":"https://orcid.org/0009-0005-7919-0808","observed_orcids":["https://orcid.org/0009-0005-7919-0808"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lihui Xu","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0005-7919-0808","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039109846","display_name":"Jussekia Jean","orcid":"https://orcid.org/0009-0000-2183-5398","observed_orcids":["https://orcid.org/0009-0000-2183-5398"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jussekia Jean","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0000-2183-5398","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063508743","display_name":"Amit M. Deshpande","orcid":"https://orcid.org/0009-0008-3275-1104","observed_orcids":["https://orcid.org/0009-0008-3275-1104"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amit M. Deshpande","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0008-3275-1104","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003058857","display_name":"William C. Comb","orcid":"https://orcid.org/0009-0008-2934-4305","observed_orcids":["https://orcid.org/0009-0008-2934-4305"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William C. Comb","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0009-0008-2934-4305","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086712201","display_name":"Thomas D. Chittenden","orcid":"https://orcid.org/0000-0002-5419-1370","observed_orcids":["https://orcid.org/0000-0002-5419-1370"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Chittenden","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0002-5419-1370","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083047242","display_name":"Brian P. Fiske","orcid":"https://orcid.org/0000-0001-5891-4268","observed_orcids":["https://orcid.org/0000-0001-5891-4268"]},"institutions":[{"id":"https://openalex.org/I4405267374","display_name":"Mythic Therapeutics, Inc. (United States)","ror":"https://ror.org/02f6prq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267374"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian P. Fiske","raw_affiliation_strings":["Mythic Therapeutics Inc., Waltham, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0001-5891-4268","affiliations":[{"raw_affiliation_string":"Mythic Therapeutics Inc., Waltham, Massachusetts","institution_ids":["https://openalex.org/I4405267374"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5002466763"],"corresponding_institution_ids":["https://openalex.org/I4405267374"],"apc_list":null,"apc_paid":null,"fwci":2.3948,"has_fulltext":true,"cited_by_count":16,"citation_normalized_percentile":{"value":0.88918733,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":97,"max":98},"biblio":{"volume":"23","issue":"9","first_page":"1282","last_page":"1293"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8241999745368958,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.8241999745368958,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0835999995470047,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9010000228881836},{"id":"https://openalex.org/keywords/c-met","display_name":"c-Met","score":0.9660000205039978},{"id":"https://openalex.org/keywords/ph-dependent-binding","display_name":"pH-dependent binding","score":0.7850000262260437},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.7789999842643738},{"id":"https://openalex.org/keywords/monomethyl-auristatin-e","display_name":"monomethyl auristatin E","score":0.9049999713897705},{"id":"https://openalex.org/keywords/payload-delivery","display_name":"payload delivery","score":0.6209999918937683},{"id":"https://openalex.org/keywords/receptor-internalization","display_name":"receptor internalization","score":0.7089999914169312},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6800000071525574},{"id":"https://openalex.org/keywords/repeated-dose-toxicity","display_name":"repeated-dose toxicity","score":0.6740000247955322},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7080000042915344}],"concepts":[{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.7897031307220459},{"id":"https://openalex.org/C134066672","wikidata":"https://www.wikidata.org/wiki/Q1424639","display_name":"Payload (computing)","level":3,"score":0.6142703890800476},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5785232782363892},{"id":"https://openalex.org/C2779820397","wikidata":"https://www.wikidata.org/wiki/Q1392806","display_name":"Drug delivery","level":2,"score":0.5558583736419678},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5547081828117371},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.4745955169200897},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4393876791000366},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4369204640388489},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3567282557487488},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.25558674335479736},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.21191972494125366},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.06552156805992126},{"id":"https://openalex.org/C158379750","wikidata":"https://www.wikidata.org/wiki/Q214111","display_name":"Network packet","level":2,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0},{"id":"https://openalex.org/C31258907","wikidata":"https://www.wikidata.org/wiki/Q1301371","display_name":"Computer network","level":1,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006863","descriptor_name":"Hydrogen-Ion Concentration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D019859","descriptor_name":"Proto-Oncogene Proteins c-met","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D019859","descriptor_name":"Proto-Oncogene Proteins c-met","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1158/1535-7163.mct-23-0784","doi":"https://doi.org/10.1158/1535-7163.mct-23-0784","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-23-0784","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11372359","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11372359","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11372359/pdf/mct-23-0784.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Mol Cancer Ther","raw_type":"Text"},{"id":"pmid:38684230","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38684230","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmid:38853438","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38853438","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.mct-23-0784","doi":"https://doi.org/10.1158/1535-7163.mct-23-0784","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-23-0784","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4396561073.pdf","grobid_xml":"https://content.openalex.org/works/W4396561073.grobid-xml"},"referenced_works_count":32,"referenced_works":["https://openalex.org/W2003723671","https://openalex.org/W2021865808","https://openalex.org/W2057031051","https://openalex.org/W2094308406","https://openalex.org/W2101581271","https://openalex.org/W2116150122","https://openalex.org/W2122895515","https://openalex.org/W2144147853","https://openalex.org/W2160725767","https://openalex.org/W2270265950","https://openalex.org/W2295236527","https://openalex.org/W2516929867","https://openalex.org/W2530716940","https://openalex.org/W2578029714","https://openalex.org/W2604488177","https://openalex.org/W2797057269","https://openalex.org/W2906954249","https://openalex.org/W2927343984","https://openalex.org/W2976352116","https://openalex.org/W2981031729","https://openalex.org/W2984395468","https://openalex.org/W3009518972","https://openalex.org/W3091969156","https://openalex.org/W3093030175","https://openalex.org/W3125295328","https://openalex.org/W3164609895","https://openalex.org/W3194878909","https://openalex.org/W4225464100","https://openalex.org/W4317932204","https://openalex.org/W4322758105","https://openalex.org/W4379333976","https://openalex.org/W4380320004"],"related_works":["https://openalex.org/W4362542942","https://openalex.org/W4393090518","https://openalex.org/W4389239705","https://openalex.org/W4409690019","https://openalex.org/W4415940675","https://openalex.org/W4379281016","https://openalex.org/W4393100568","https://openalex.org/W4394693015","https://openalex.org/W4410803169","https://openalex.org/W2987115036"],"abstract_inverted_index":{"Advances":[0],"in":[1,16,53,102,138,217],"linker":[2],"payload":[3,39],"technology":[4],"and":[5,109,158,212],"target":[6],"selection":[7],"have":[8],"been":[9],"at":[10,129],"the":[11,26,31,54,66,78,182,209],"forefront":[12],"of":[13,33,50,57,85,116,126,142,184,191,215],"recent":[14],"improvements":[15],"antibody-drug":[17],"conjugate":[18],"(ADC)":[19],"design,":[20],"leading":[21],"to":[22,37,41,80,147,173,207],"several":[23],"approvals":[24],"over":[25,156],"last":[27],"decade.":[28],"In":[29,161],"contrast,":[30],"potential":[32,79,183],"novel":[34],"ADC":[35,62,101,137],"technologies":[36],"enhance":[38],"delivery":[40],"tumors":[42],"is":[43,205],"relatively":[44],"underexplored.":[45],"We":[46],"demonstrate":[47],"that":[48,76],"incorporation":[49],"pH-dependent":[51],"binding":[52],"antibody":[55],"component":[56],"a":[58,82,98,114,135,162,169,188],"c-mesenchymal-epithelial":[59],"transition":[60],"(MET)-targeting":[61],"(MYTX-011)":[63],"can":[64],"overcome":[65],"requirement":[67],"for":[68,186],"high":[69,148],"c-MET":[70,89,149,196],"expression":[71,197],"on":[72],"tumors,":[73],"an":[74],"innovation":[75],"has":[77],"benefit":[81],"broader":[83,189],"population":[84],"patients":[86,192,218],"with":[87,193,195,219],"lower":[88],"levels.":[90],"MYTX-011":[91,127,152,167,185,216],"drove":[92],"fourfold":[93],"higher":[94,132],"net":[95],"internalization":[96],"than":[97,134,198],"non-pH-engineered":[99],"parent":[100,157],"non-small":[103],"cell":[104,117],"lung":[105],"cancer":[106],"(NSCLC)":[107],"cells":[108],"showed":[110,128,153],"increased":[111],"cytotoxicity":[112],"against":[113],"panel":[115],"lines":[118],"from":[119,145],"various":[120],"solid":[121],"tumors.":[122],"A":[123,202],"single":[124],"dose":[125,164],"least":[130],"threefold":[131],"efficacy":[133,214],"benchmark":[136,159],"mouse":[139],"xenograft":[140],"models":[141],"NSCLC":[143,194,220],"ranging":[144],"low":[146],"expression.":[150],"Moreover,":[151],"improved":[154],"pharmacokinetics":[155],"ADCs.":[160,178,201],"repeat":[163],"toxicology":[165],"study,":[166],"exhibited":[168],"toxicity":[170],"profile":[171],"similar":[172],"other":[174,199],"monomethyl":[175],"auristatin":[176],"E-based":[177],"These":[179],"results":[180],"highlight":[181],"treating":[187],"range":[190],"c-MET-targeting":[200],"first-in-human":[203],"study":[204],"ongoing":[206],"determine":[208],"safety,":[210],"tolerability,":[211],"preliminary":[213],"(NCT05652868).":[221]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":5}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2024-05-02T00:00:00"}